Unexpected suppression of neuronal G protein-activated, inwardly rectifying K+ current by common phospholipase C inhibitor.
Stabilization of the binding of phosphatidylinositol bisphosphate (PIP(2)) to G protein-coupled inward rectifier K+ (GIRK) channels is essential for their activation, whereas hydrolysis of PIP(2) by phospholipase C (PLC) inhibits channel activity. Apparently inconsistent with this mechanism, we found that the commonly used PLC inhibitor, U73122 (1 microM), produced a significant reduction in the amplitude of baclofen (20 microM)-evoked GIRK currents in whole-cell recordings from acutely isolated rat neocortical pyramidal cells. Also, U73122 reduced the percentage of baclofen-responsive neurons from 100% (n=40) to 56% (n=25). Since NCDC (100 microM), a PLC inhibitor of another molecular class, displayed no effect on GIRK current amplitude or responsiveness (100%, n=6), inhibition of PLC is unlikely to account for the effects of U73122 in our preparation. Lending further support to this notion, the structurally closely related compound, U73343, which does not inhibit PLC, proved to be even more efficient in suppressing GIRK current as compared to U73122. In neurons, in which GIRK channels were irreversibly activated by GTPgammaS (n=10), the depressant action of U71322 was fully preserved. These findings hint at a direct interaction of U73122 with the GIRK channel or a closely associated protein. Caution is therefore warranted when employing this compound to examine the role of PLC and PIP(2) in the regulation of GIRK channel activity.
Sickmann
Thomas
T
Institute of Physiology, University of Munich, 80336 Munich, Germany.
Klose
Angelika
A
Huth
Tobias
T
Alzheimer
Christian
C
D000241:Adenosine / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001418:Baclofen / Q000494:pharmacology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004963:Estrenes / Q000494:pharmacology*; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels / Q000502:physiology*; D018755:GABA Agonists / Q000494:pharmacology; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D009433:Neural Inhibition / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D017966:Pyramidal Cells / Q000187:drug effects*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D013003:Somatosensory Cortex / Q000166:cytology
D000700:Analgesics; D004963:Estrenes; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D018755:GABA Agonists; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D001418:Baclofen; D000241:Adenosine